NCT06432296View on ClinicalTrials.gov

Treatment of Malignant Ascites Caused by Advanced Epithelial Solid Tumors With M701 Bispecific Antibody

PHASE3Active, not recruitingINTERVENTIONAL
Enrollment

312

Participants

Timeline

Start Date

March 20, 2024

Primary Completion Date

November 3, 2025

Study Completion Date

January 30, 2026

Conditions
Malignant Ascites
Interventions
DRUG

M701

Intra-peritoneal infusion of M701 in experimental group (M701 group\_

PROCEDURE

paracentesis

Puncture and Draiange of ascites from the peritoneal cavity in both experimental group and control group

Trial Locations (2)

100141

The First Medical Center of Chinese PLA General Hospital, Beijing

150081

Harbin Medical University Cancer Hospital, Harbin

All Listed Sponsors
lead

Wuhan YZY Biopharma Co., Ltd.

INDUSTRY